HOPE Pilot Quantitative Raw Data (Feasibility, Appropriateness, Acceptability, Clinical Effectiveness Outcome measures)

The Hypermobile Online Pain managemEnt (HOPE) program was developed for people with painful hypermobility syndromes and was pilot tested in this present study. We conducted a pilot randomised controlled trial to assess Feasibility of Intervention Measure (FIM), Acceptability of Intervention Measure (AIM) and Intervention Appropriateness Measure (IAM) as well as clinical effectiveness outcomes including brief pain inventory, bristol impact of hypermobility, DASS, pain self-efficacy and global impression of change (see readme files for names of all questionnaires used). Outcomes were assessed using online surveys at baseline, post-treatment and 3-months post-treatment. Results showed that the HOPE program was feasible, acceptable and appropriate, with some improvements in pain and impact of hypermobility. A fully powered trial is warranted to further explore clinical effectiveness of the program.This is the raw data from this pilot randomised controlled trial of the "HOPE for hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorder (HSD) – A pilot randomized controlled trial of feasibility, acceptability and appropriateness" study. MQ HREC approval was gained (520231630154261) and the ANZCTR registration is ACTRN12623001323617.